Board of Directors | Investor Relation | Diagnostics | Gentian
medical, diagnostics, immunoassays, assays, in vitro diagnostics, IVD products, avian antibodies, antibodies, clinical chemistry, diagnostic tests, biotechnology
page-template,page-template-full_width,page-template-full_width-php,page,page-id-15903,page-child,parent-pageid-15340,ajax_fade,page_not_loaded,,qode-content-sidebar-responsive,qode-child-theme-ver-1.0.0,qode-theme-ver-14.2,qode-theme-bridge,wpb-js-composer js-comp-ver-5.7,vc_responsive

Board of Directors

Board of Directors

Tomas Settevik

Chairman of the board

Tomas Settevik has experience in both life sciences and retailing, and is currently an independent investor and non-exec director in several companies. He was the CEO of Stokke AS (2010-15), and CEO of Pronova BioPharma ASA after serving as Vice President Pharmaceuticals and Manufacturing (2004-2009). Mr. Settevik has also held several senior positions – VP Northern Europe, VP Marketing and R&D, and Managing Director UK/Nordic – at Tyco Healthcare EMEA (acquired by Medtronic) (1992-2003). 

Mr. Settevik holds a degree from Copenhagen Business School.

Espen Tidemann Jørgensen

Board member

Espen Tidemann Jørgensen is currently Portfolio Manager of Holta Invest AS and Managing Director of Holta Life Sciences AS, the largest shareholder in Gentian Diagnostics.  He has 18 years of experience from financial markets as equity analyst at DNB Markets and portfolio manager at Holta Invest. Mr. Jørgensen has previously been a member of the Board of Directors at Weifa ASA and Cortendo (now Strongbridge BioPharma). He is currently a board member at Decisions AS in addition to Gentian Diagnostics

Mr. Jørgensen holds a Master’s degree in Economics and has completed 3 years of Medicine studies at the University of Oslo.

Ingrid Teigland Akay

Board member

Ingrid Teigland Akay is a life science investor and medical doctor. Over the last decade she has invested into and worked with portfolio companies in the healthcare sector across Europe, US and Asia. She has previously served as a Senior Investment Manager at Inventages in London. Ms. Akay also has broad clinical experience in internal medicine and surgery at Scandinavian and UK hospitals. Today she is Managing Partner of Hadean Ventures, a life science investment firm with a focus on the Nordics.

Ms. Akay holds a medical degree from Medizinische Hochschule Hannover and an MBA in Finance from London Business School.

Kari E. Krogstad

Board member

Kari Krogstad has more than 25 years of experience from the biomedical industry, from commercial leadership roles within the pharma, biotech and medtech sectors. She has worked for Dynal Biotech, where she has led Invitrogen Dynal in the role as General Manager after the acquisition from Invitrogen in 2005. Ms. Krogstad has held her current role as President and CEO at Medistim ASA since 2009.

Ms. Krogstad holds a Cand. Scient. degree in Molecular Biology from the University of Oslo as well as a Business degree from IHM Business School.

Bendik H. Sundrehagen

Board member

Bendik H. Sundrehagen is Doctor of Medicine (MD) and a specialist in pathology. He has extensive training from Pathology at Fredrikstad Hospital and Dept. of Forensic Pathology at Fokehelseinstituttet (2010-2015). He currently holds a position as Pathologist at Kalnes Hospital with main responsibilities in Gastrointestinal-, Genitourinary- and Pulmonary histopathology and cytology. Mr. Sundrehagen also owns the company Safrino AS.

Mr. Sundrehagen graduated from Medical school, Oslo University in 2008.

Henrik Krefting

Board member

Henrik Krefting has significant experience in the investment industry over a period of 20 years. He is CEO / CIO of Vatne Capital AS since January 2017. Mr. Krefting has previously worked as Investment Director of Pactum AS (2006 to 2016) and Investment Manager of Kistefos AS (1998 to 2006). He has also held a senior analyst position in the strategy consulting firm Innovation AS. Mr. Krefting has had numerous directorships linked to active ownership through direct investments.

Mr. Krefting holds an MSC from London School of Economics and Social Science and a BSc from Warwick University.